alpha beta depletion

Phase 2Small molecule

MMitchell Cairo

alpha beta depletion is one of 3 small molecule programs targeting Hematologic Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hematologic DiseaseRecruiting

Hematologic DiseasePhase 2

Recruiting

Competition

Competitive Landscape

2 competitors in Hematologic Disease

#DrugCompanyPhaseTrials

Simulect

Novartis

Phase 2

1 2

alpha beta depletion

MMitchell Cairo

Phase 2

1 3

CD70 CAR-T Cells

CChongqing Precision Biotech Co., Ltd

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Hematologic Disease

NCT04099966

Clinical

Trials by Indication[1]

Hematologic Disease1 trial

AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion

Recruiting·MMitchell Cairo·Phase 2·NCT04099966·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for alpha beta depletion. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — alpha beta depletion compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for alpha beta depletion. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mitchell Cairo company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MMitchell Cairo

alpha beta depletion

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Hematologic Disease1 trial

References

Drug Info

Quick Facts

Related News